Dr. Torti has served as a member of our board since September 2018. He has also served as Vant Investment Chair for Roivant Sciences since August 2018. Prior to Roivant, Dr. Torti was at New Enterprise Associates (NEA), a leading venture capital firm where he served as partner. At NEA, Dr. Torti managed early and growth-stage investments in numerous healthcare companies that were responsible for the development and commercialization of new drugs and medical devices important to clinical medicine today. Prior to joining NEA in 2007, Dr. Torti was a researcher at the Duke University Center for Clinical & Genetic Economics where he was involved in clinical trials research and economic evaluations of multinational clinical trials. Dr. Torti received his M.D. from the University of North Carolina School of Medicine and his M.B.A. with distinction from Harvard Business School. 

Frank Torti, MD — Chairperson of the Board of Directors

Dr. Pande has served as a member of the board since March 2015. He serves as Chief Medical Advisor of PureTech Health, President of Verity BioConsulting, a drug development consulting firm, and Chief Medical Officer of Tal Medical, a clinical-stage medical device company. From 2007 to April 2014, Dr. Pande was Senior Vice President and Senior Advisor, Pharmaceutical R&D, at GlaxoSmithKline. He has also held senior roles at Pfizer R&D, Parke-Davis/Warner-Lambert and Lilly Research Laboratories. Dr. Pande is also a non-executive board member of Autifony Therapeutics and Karuna Pharmaceuticals. Dr. Pande received a Bachelor of Medicine, Bachelor of Surgery (MBBS) degree from the University of Lucknow, India, and completed his research fellowship training in psychiatry at the University of Michigan Medical School and postgraduate specialty training and psychiatry residency program at Western University.

Atul Pande, MD — Lead Independent Director

Ms. Potter has served as a member of our board since September 2018. She has also served as Vant Operating Chair for Roivant Sciences since July 2018. Ms. Potter founded Myrtle Potter & Company, LLC, a private healthcare and life sciences consulting firm and served as the Chief Executive Officer until she joined Roivant. Ms. Potter previously served as President and Chief Operating Officer of Genentech during a pivotal period of the company’s growth. Under her leadership, Genentech achieved record sales and earnings growth each year. Prior to Genentech, she was president of Bristol-Myers Squibb’s U.S. Cardiovascular and Metabolic business and a vice president at Merck & Co. She is a graduate of the University of Chicago and serves on the university’s board of trustees. She also serves on the boards of Rite Aid and Liberty Mutual Insurance Group, and previously served on the boards of Amazon, Express Scripts, and Medco Health Solutions.

Myrtle Potter

Pavan Cheruvu, MD was named Axovant’s Chief Executive Officer in February 2018 and was appointed a member of the board in September 2018. Prior to joining Axovant, Dr. Cheruvu held roles of increasing responsibility at Roivant Sciences and was appointed to Roivant’s executive leadership team in 2017. He supported Axovant in numerous capacities throughout his time at Roivant. A board-certified physician, Dr. Cheruvu completed his residency in internal medicine at Johns Hopkins Hospital and continued his training in a clinical fellowship in cardiovascular medicine at the University of California, San Francisco. Prior to his medical training, Dr. Cheruvu was a management consultant at McKinsey & Company, where he focused on biopharmaceutical strategy. Dr. Cheruvu earned his B.S.E. in biomedical engineering, B.S.E. in electrical engineering, and A.B. in chemistry summa cum laude from Duke University, obtained his M.Sc. in computer science as a Rhodes Scholar at Oxford University, and obtained his M.D. from Harvard Medical School.

Pavan Cheruvu, MD

Mr. Bickerstaff has served as a member of Axovant’s board since February 2018. Mr. Bickerstaff is currently a partner and the managing director of M.M. Dillon & Co., a healthcare and technology investment bank that he co-founded in 2005. He was Chief Financial Officer of Novartis Pharma AG from 2000 to 2005. Before joining Novartis, Mr. Bickerstaff served as CFO to several other companies and he has served on the boards of directors for multiple public companies in the healthcare industry, including ARIAD Pharmaceuticals and Innoviva. Mr. Bickerstaff received his B.S. in engineering and his B.A. in business administration from Rutgers University and he continued his executive education at Harvard Business School.

George Bickerstaff

Mr. Modig has served as a member of the board since March 2015. He also serves as Chief Executive Officer of Pharvaris B.V. Previously, he served as Chief Financial Officer of Prosensa Holding N.V., a pharmaceutical company, from March 2010 until its acquisition by BioMarin Pharmaceutical Inc. in January 2015. From October 2003 to November 2008, Mr. Modig was Chief Financial Officer at Jerini AG where he directed private financing rounds, the company’s initial public offering in 2005, and its acquisition by Shire plc in 2008. Before that, Mr. Modig served as Chief Financial Officer at Surplex AG from 2001 to 2003 and as Finance Director Europe of U.S.-based Hayward Industrial Products Inc. from 1999 to 2001. In previous positions, Mr. Modig was a Partner in the Brussels-based private equity firm Agra Industria from 1994 to 1999 and a Senior Manager in the Financial Services Industry Group of Price Waterhouse LLP in New York from 1991 to 1994. Mr. Modig currently serves as a director and member of the Audit Committee of Affimed N.V. – a publicly held pharmaceutical company. He also serves on the supervisory board of Kiadis Pharma N.V. and was a director of Mobile Loyalty plc from 2012 to 2013. Mr. Modig received a bachelor’s degree in business administration, economics, and German from the University of Lund, Sweden, and an M.B.A. from INSEAD, Fontainebleau, France.

Berndt Modig

Ilan Oren has served as Vice President, Business Development at Dexcel Pharma Technologies Ltd., an international pharmaceutical company involved in the development, manufacture, and commercialization of pharmaceuticals, since September 2011. From 2007 to July 2011, he was employed by L.E.K. Consulting and advised clients in the life sciences sector on corporate strategy, mergers and acquisitions, licensing and drug commercialization projects. Mr. Oren currently serves as a director of Cynapsus Therapeutics Inc., a publicly traded specialty pharmaceutical company, and as a director of Roivant Sciences. Mr. Oren received his B.A. in Economics from Harvard College.

Ilan Oren

Mr. Sundaram has served as a member of our board since June 2019. He was most recently the Chief Financial Officer at Nightstar Therapeutics, until its acquisition by Biogen in June 2019. While at Nightstar, he was responsible for corporate finance and operations, business development, and strategy. He helped lead the execution of multiple equity offerings, as well as licensing and M&A transactions. Prior to joining Nightstar, Mr. Sundaram was the Vice President and Head of Business and Corporate Development at Intercept Pharmaceuticals, Inc. Previously, Mr. Sundaram spent 13 years in the healthcare investment banking groups at Lehman Brothers/Barclays, Citigroup and Lazard. Mr. Sundaram holds a B.S. in Computer Engineering and a B.A. in Economics from Brown University.

Senthil Sundaram
 
 

AXOVANT GENE THERAPIES

Eleven Times Square, 33rd Floor
New York, NY 10036
United States

+1-833-AXOVANT (1-833-296-8268)

  • Axovant Gene Therapies LinkedIn
  • Axovant Gene Therapies Twitter
  • Axovant Gene Therapies Facebook

AXOVANT SCIENCES GMBH

Viaduktstrasse 8
4051 Basel
Switzerland